Developer docs
API playgroundTry for free, no card

Search company profiles

Aquestive Therapeutics

Full company profile

uuid0000x9e

Namestring
Aquestive Therapeutics
Legal namestring
Aquestive Therapeutics, Inc.
Websiteurl
aquestive.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Aquestive Therapeutics is a US specialty pharmaceutical company that develops, manufactures, and commercializes medicines using two proprietary drug delivery platforms. The PharmFilm platform delivers active pharmaceutical ingredients via dissolvable sublingual, buccal, and lingual films and has supported over 2.5 billion doses shipped worldwide across products available on six continents. The AdrenaVerse platform is a proprietary library of more than 20 epinephrine prodrugs with patent protection extending to 2037, enabling controlled epinephrine absorption across mucosal and dermal dosage forms including lotions, creams, and ointments.

The company's commercial revenue comes from three streams: (1) licensing and royalties on four FDA-approved products commercialized by partners — Sympazan (Assertio Holdings), Suboxone (Indivior), Emylif (Zambon UK), and Ondif (Hypera Pharma SA); (2) a CDMO (Contract Development and Manufacturing Organization) business offering FDA-compliant, DEA-registered manufacturing and DSCSA-serialized packaging at two Indiana facilities totaling 34,400+ square feet; and (3) planned direct commercialization of its proprietary pipeline assets Anaphylm (dibutepinephrine sublingual film for anaphylaxis) and Libervant (diazepam buccal film for seizure clusters). The Anaphylm NDA received a Complete Response Letter from the FDA in January 2026 citing human factors and packaging deficiencies, and the company plans a Q3 2026 resubmission. Aquestive employs 101–250 people, is headquartered in Warren, New Jersey, and trades on NASDAQ as AQST following its 2018 IPO.

Short descriptiontext

Aquestive Therapeutics is a US specialty pharmaceutical company that develops and manufactures proprietary oral film (PharmFilm) and epinephrine prodrug (AdrenaVerse) drug delivery technologies, licensing FDA-approved products to pharma partners and operating a CDMO services business, with a pipeline led by Anaphylm for anaphylaxis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWarren, United States
HQ citystring
Warren
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral film drug delivery, specialty pharmaceutical products, pharmaceutical CDMO services, epinephrine delivery systems, sublingual buccal film technology
Industry1 code
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Licensing & Royalty Revenue
TypeLicensing Royalties
Description

Aquestive licenses its PharmFilm technology and proprietary products to pharmaceutical companies. Revenue is generated through licensing fees, milestone payments, and ongoing royalties on net sales of licensed products. Four products are currently commercialized by licensees: Sympazan (Assertio Holdings), Suboxone (Indivior), Emylif (Zambon UK Limited), and Ondif (Hypera Pharma SA).

aquestive.com
2CDMO Manufacturing & Packaging Services
TypeProfessional Services
Description

Aquestive operates as a Contract Development and Manufacturing Organization (CDMO), providing FDA-compliant manufacturing and packaging services for pharmaceutical, OTC, and wellness products. Services include oral film production, topical/liquid packaging, serialization, and regulatory support. Revenue is generated through service fees for development, manufacturing, and packaging of client products.

aquestive.com
3Proprietary Product Commercialization
TypeOne Time License
Description

Upon FDA approval of Anaphylm (dibutepinephrine sublingual film) and Libervant (diazepam buccal film), Aquestive plans to commercialize these proprietary products directly or through co-promotion agreements. Revenue will be generated through product sales. The company has built out commercial infrastructure including a Chief Commercial Officer and is preparing for launch.

aquestive.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1PharmFilm
Description

Proprietary oral film drug delivery technology platform enabling precise dosing through buccal, sublingual, and lingual film options.

aquestive.com
+3 more records
Core offering1 text field

Aquestive Therapeutics is a specialty pharmaceutical company that develops, licenses, and manufactures pharmaceutical products using its proprietary PharmFilm oral film drug delivery technology and AdrenaVerse epinephrine prodrug platform. The company generates revenue through licensing its technology and FDA-approved products to pharmaceutical partners (Sympazan, Suboxone, Emylif, Ondif), providing CDMO manufacturing and packaging services to third-party brands, and advancing a proprietary pipeline (Anaphylm, Libervant, AQST-108) toward direct commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 2.5 billion PharmFilm doses shipped worldwide
+3 more records
Product overview1 text field

Aquestive Therapeutics is a pharmaceutical company advancing medicines through innovative drug delivery technologies. The company's portfolio centers on two proprietary technology platforms: PharmFilm, a proven oral film drug delivery system enabling sublingual, buccal, and lingual administration; and AdrenaVerse, a novel epinephrine prodrug platform for localized delivery. The pipeline includes Anaphylm (dibutepinephrine sublingual film) for severe allergic reactions and Libervant (diazepam buccal film) for seizure clusters, both leveraging PharmFilm technology. The company commercializes multiple FDA-approved products through licensees including Sympazan, Suboxone, Emylif, and Ondif. Beyond proprietary products, Aquestive operates a contract development and manufacturing (CDMO) business offering pharmaceutical manufacturing and packaging services.

Product and service11 records
1Anaphylm (dibutepinephrine) Sublingual Film
CategoryPipeline Product (Specialty Pharmaceutical)
Description

First orally delivered film formulation of epinephrine in clinical development for emergency treatment of severe allergic reactions including anaphylaxis. Developed using PharmFilm and AdrenaVerse technologies, designed for rapid non-invasive epinephrine delivery without injection.

2Libervant (diazepam) Buccal Film
CategoryPipeline Product (Specialty Pharmaceutical)
Description

First and only orally-administered, non-device diazepam product candidate for treatment of seizure clusters in children ages 2-5 years and patients 12 and older. Discreet, mint-flavored dissolving film delivered using PharmFilm technology.

3AQST-108 (epinephrine) Topical Gel
CategoryPipeline Product (Specialty Pharmaceutical)
Description

Epinephrine topical gel product candidate using AdrenaVerse platform technology for potential multiple indications in dermatology.

4PharmFilm Technology Platform (Licensed)
CategoryTechnology Platform (Drug Delivery)
Description

Proprietary drug delivery platform enabling precise oral delivery of active pharmaceutical ingredients through small dissolvable films without water or swallowing. Supports sublingual, buccal, and lingual administration routes. Licensed to pharmaceutical companies for use in their commercialized products.

5AdrenaVerse Technology Platform (Licensed)
CategoryTechnology Platform (Drug Delivery)
Description

Proprietary prodrug platform containing library of over 20 epinephrine prodrugs enabling localized, sustained epinephrine delivery across mucosal and dermal surfaces through lotions, creams, and ointments. Patent protection through 2037.

6Sympazan (clobazam) Oral Film
CategoryCommercialized Product (via Licensee)
Description

FDA-approved oral film formulation of clobazam commercialized by Assertio Holdings using Aquestive's PharmFilm technology for treatment of seizures.

7Suboxone (buprenorphine and naloxone) Sublingual Film
CategoryCommercialized Product (via Licensee)
Description

FDA-approved sublingual film formulation commercialized by Indivior Inc. using PharmFilm technology for opioid dependence treatment.

8Emylif (riluzole) Film Orodispersible
CategoryCommercialized Product (via Licensee)
Description

FDA-approved riluzole film orodispersible product commercialized by Zambon UK Limited using Aquestive's PharmFilm technology for ALS treatment.

9Ondif (ondansetron) Oral Film
CategoryCommercialized Product (via Licensee)
Description

Ondansetron orodisposable film product commercialized by Hypera Pharma SA using Aquestive's PharmFilm technology for nausea and vomiting treatment.

10CDMO Contract Manufacturing Services
CategoryContract Manufacturing Services (CDMO)
Description

Full-scale FDA-compliant contract manufacturing services including oral film production (2.5+ billion doses produced), clinical to commercial scale, cGMP manufacturing, QA/QC, and controlled substance handling with DEA registration. Two Indiana facilities totaling 34,400+ ft² of GMP space serving pharmaceutical, OTC, and wellness brand clients.

11Packaging Services
CategoryContract Packaging Services (CDMO)
Description

High-throughput US-based packaging and serialization services for liquid, creams, topicals, gels, semi-solids, and oral film products. Fully DSCSA-compliant serialized packaging with artwork, labeling, and final assembly support.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Assertio Holdings, Inc.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Assertio Holdings commercializes Sympazan (clobazam) oral film, an FDA-approved product utilizing Aquestive's PharmFilm technology. This is a licensing arrangement where Aquestive's technology is embedded in a commercialized pharmaceutical product.

aquestive.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Indivior commercializes Suboxone (buprenorphine and naloxone) sublingual film, an FDA-approved product utilizing Aquestive's PharmFilm technology. Suboxone was one of Aquestive's first two FDA-approved products in 2010.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Zambon UK Limited commercializes Emylif (riluzole) film orodispersible, an FDA-approved product utilizing Aquestive's PharmFilm technology for ALS treatment.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Hypera Pharma SA commercializes Ondif (ondansetron) orodisposable film utilizing Aquestive's PharmFilm technology for nausea and vomiting treatment.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

IntelGenx is a specialty drug delivery company built around proprietary oral thin film technology, with a business model combining proprietary product development (similar to Aquestive's Anaphylm/Libervant pipeline) and CDMO/licensing partnerships (similar to Aquestive's Sympazan/Suboxone licensees). Both companies focus on transforming approved APIs into differentiated film-based dosage forms for partners.

TypeDirect peer
Description

LTS is a global leader in transdermal and oral thin film drug delivery systems, operating both proprietary development and contract development/manufacturing (CDMO) businesses. It is one of the most direct comparables to Aquestive's combined platform-plus-CDMO model and competes for similar pharmaceutical licensing partnerships.

TypeBroad incumbent
Description

Catalent is a large, publicly traded global CDMO offering oral, injectable, and other drug delivery capabilities across a broad portfolio. While not specialized in oral thin films like Aquestive, Catalent competes for the same pharmaceutical CDMO customers and licensing partnerships and represents the scaled incumbent benchmark for the CDMO segment of Aquestive's business.

TypeBroad incumbent
Description

Viatris owns the EpiPen franchise, the dominant injectable epinephrine rescue therapy and the direct competitive incumbent for Aquestive's Anaphylm. Viatris also licenses Suboxone sublingual film from Aquestive via its Indivior relationship history and is a critical reference point for assessing Anaphylm's addressable market and switching dynamics.

TypeEmerging player
Description

Neurelis developed Valtoco, a diazepam nasal spray approved for seizure clusters, positioning it as a direct therapeutic-area competitor to Aquestive's Libervant (diazepam buccal film). Both target the same patient population (seizure clusters in epilepsy) with non-injectable, non-rectal delivery alternatives and compete for similar neurology specialist and pediatric prescribing relationships.

TypeEmerging player
Description

BioDelivery Sciences (now part of Collegium Pharmaceutical) was a specialty pharma that commercialized film-based and buccal opioid products using its proprietary drug delivery platform. Its model of licensing and direct commercialization of differentiated formulations in CNS/pain indications is highly comparable to Aquestive's license-and-pipeline strategy.

TypeBroad incumbent
Description

Collegium is a specialty pharma focused on pain and CNS indications with a portfolio that includes film-based and abuse-deterrent products. Its specialty commercial model and CNS/pain therapeutic focus overlap meaningfully with Aquestive's planned direct commercialization of Libervant and CNS pipeline ambitions.

TypeEmerging player
Description

Eagle Pharmaceuticals is a small-cap specialty pharma that develops and commercializes differentiated formulations of existing molecules, often through partnerships. Its specialty commercial infrastructure, small molecule reformulation focus, and reliance on licensing partners place it in a similar size and business model tier to Aquestive.

9Tapemark
TypeEmerging player
Description

Tapemark is a private contract manufacturer specializing in transdermal patches and oral thin film drug delivery. It competes directly with Aquestive's CDMO segment for pharmaceutical and OTC brand customers seeking US-based film manufacturing capabilities, and its scale and capabilities are a useful comparator for that segment of Aquestive's business.

10Assertio Holdings
TypeOthers
Description

Assertio is the licensee that commercializes Aquestive's Sympazan (clobazam oral film) and also markets other specialty neurology products. As a direct commercial partner and adjacent specialty pharma operator, Assertio provides useful comparability for the economics and execution requirements of Aquestive's licensee model.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aquestive Therapeutics

Specialty Pharmaceuticalsaquestive.com

Aquestive Therapeutics is a US specialty pharmaceutical company that develops and manufactures proprietary oral film (PharmFilm) and epinephrine prodrug (AdrenaVerse) drug delivery technologies, licensing FDA-approved products to pharma partners and operating a CDMO services business, with a pipeline led by Anaphylm for anaphylaxis.

What Aquestive Therapeutics does

Aquestive Therapeutics is a US specialty pharmaceutical company that develops, manufactures, and commercializes medicines using two proprietary drug delivery platforms. The PharmFilm platform delivers active pharmaceutical ingredients via dissolvable sublingual, buccal, and lingual films and has supported over 2.5 billion doses shipped worldwide across products available on six continents. The AdrenaVerse platform is a proprietary library of more than 20 epinephrine prodrugs with patent protection extending to 2037, enabling controlled epinephrine absorption across mucosal and dermal dosage forms including lotions, creams, and ointments.

The company's commercial revenue comes from three streams: (1) licensing and royalties on four FDA-approved products commercialized by partners — Sympazan (Assertio Holdings), Suboxone (Indivior), Emylif (Zambon UK), and Ondif (Hypera Pharma SA); (2) a CDMO (Contract Development and Manufacturing Organization) business offering FDA-compliant, DEA-registered manufacturing and DSCSA-serialized packaging at two Indiana facilities totaling 34,400+ square feet; and (3) planned direct commercialization of its proprietary pipeline assets Anaphylm (dibutepinephrine sublingual film for anaphylaxis) and Libervant (diazepam buccal film for seizure clusters). The Anaphylm NDA received a Complete Response Letter from the FDA in January 2026 citing human factors and packaging deficiencies, and the company plans a Q3 2026 resubmission. Aquestive employs 101–250 people, is headquartered in Warren, New Jersey, and trades on NASDAQ as AQST following its 2018 IPO.

Aquestive Therapeutics firmographics

Firmographics
Name
Aquestive Therapeutics
Legal name
Aquestive Therapeutics, Inc.
Website
https://aquestive.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Aquestive Therapeutics is a US specialty pharmaceutical company that develops and manufactures proprietary oral film (PharmFilm) and epinephrine prodrug (AdrenaVerse) drug delivery technologies, licensing FDA-approved products to pharma partners and operating a CDMO services business, with a pipeline led by Anaphylm for anaphylaxis.
Ownership category
akta.pro rank

Aquestive Therapeutics industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Oral film drug delivery
  • Specialty pharmaceutical products
  • Pharmaceutical CDMO services
  • Epinephrine delivery systems
  • Sublingual buccal film technology

Where Aquestive Therapeutics is headquartered

Location

Headquarters

HQ city
Warren
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aquestive Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Product Licensing & Royalty Revenue: Aquestive licenses its PharmFilm technology and proprietary products to pharmaceutical companies. Revenue is generated through licensing fees, milestone payments, and ongoing royalties on net sales of licensed products. Four products are currently commercialized by licensees: Sympazan (Assertio Holdings), Suboxone (Indivior), Emylif (Zambon UK Limited), and Ondif (Hypera Pharma SA).
  2. CDMO Manufacturing & Packaging Services: Aquestive operates as a Contract Development and Manufacturing Organization (CDMO), providing FDA-compliant manufacturing and packaging services for pharmaceutical, OTC, and wellness products. Services include oral film production, topical/liquid packaging, serialization, and regulatory support. Revenue is generated through service fees for development, manufacturing, and packaging of client products.
  3. Proprietary Product Commercialization: Upon FDA approval of Anaphylm (dibutepinephrine sublingual film) and Libervant (diazepam buccal film), Aquestive plans to commercialize these proprietary products directly or through co-promotion agreements. Revenue will be generated through product sales. The company has built out commercial infrastructure including a Chief Commercial Officer and is preparing for launch.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Aquestive Therapeutics product offering

Product offering

Core offering

Aquestive Therapeutics is a specialty pharmaceutical company that develops, licenses, and manufactures pharmaceutical products using its proprietary PharmFilm oral film drug delivery technology and AdrenaVerse epinephrine prodrug platform. The company generates revenue through licensing its technology and FDA-approved products to pharmaceutical partners (Sympazan, Suboxone, Emylif, Ondif), providing CDMO manufacturing and packaging services to third-party brands, and advancing a proprietary pipeline (Anaphylm, Libervant, AQST-108) toward direct commercialization.

Product overview

Aquestive Therapeutics is a pharmaceutical company advancing medicines through innovative drug delivery technologies. The company's portfolio centers on two proprietary technology platforms: PharmFilm, a proven oral film drug delivery system enabling sublingual, buccal, and lingual administration; and AdrenaVerse, a novel epinephrine prodrug platform for localized delivery. The pipeline includes Anaphylm (dibutepinephrine sublingual film) for severe allergic reactions and Libervant (diazepam buccal film) for seizure clusters, both leveraging PharmFilm technology. The company commercializes multiple FDA-approved products through licensees including Sympazan, Suboxone, Emylif, and Ondif. Beyond proprietary products, Aquestive operates a contract development and manufacturing (CDMO) business offering pharmaceutical manufacturing and packaging services.

Differentiator

Problem solved

Functional benefit

Brands

  • PharmFilm: Proprietary oral film drug delivery technology platform enabling precise dosing through buccal, sublingual, and lingual film options.
  • AdrenaVerse
  • Anaphylm
  • Libervant

Products and services

  • Anaphylm (dibutepinephrine) Sublingual Film First orally delivered film formulation of epinephrine in clinical development for emergency treatment of severe allergic reactions including anaphylaxis. Developed using PharmFilm and AdrenaVerse technologies, designed for rapid non-invasive epinephrine delivery without injection.
  • Libervant (diazepam) Buccal Film First and only orally-administered, non-device diazepam product candidate for treatment of seizure clusters in children ages 2-5 years and patients 12 and older. Discreet, mint-flavored dissolving film delivered using PharmFilm technology.
  • AQST-108 (epinephrine) Topical Gel Epinephrine topical gel product candidate using AdrenaVerse platform technology for potential multiple indications in dermatology.
  • PharmFilm Technology Platform (Licensed) Proprietary drug delivery platform enabling precise oral delivery of active pharmaceutical ingredients through small dissolvable films without water or swallowing. Supports sublingual, buccal, and lingual administration routes. Licensed to pharmaceutical companies for use in their commercialized products.
  • AdrenaVerse Technology Platform (Licensed) Proprietary prodrug platform containing library of over 20 epinephrine prodrugs enabling localized, sustained epinephrine delivery across mucosal and dermal surfaces through lotions, creams, and ointments. Patent protection through 2037.
  • Sympazan (clobazam) Oral Film FDA-approved oral film formulation of clobazam commercialized by Assertio Holdings using Aquestive's PharmFilm technology for treatment of seizures.
  • Suboxone (buprenorphine and naloxone) Sublingual Film FDA-approved sublingual film formulation commercialized by Indivior Inc. using PharmFilm technology for opioid dependence treatment.
  • Emylif (riluzole) Film Orodispersible FDA-approved riluzole film orodispersible product commercialized by Zambon UK Limited using Aquestive's PharmFilm technology for ALS treatment.
  • Ondif (ondansetron) Oral Film Ondansetron orodisposable film product commercialized by Hypera Pharma SA using Aquestive's PharmFilm technology for nausea and vomiting treatment.
  • CDMO Contract Manufacturing Services Full-scale FDA-compliant contract manufacturing services including oral film production (2.5+ billion doses produced), clinical to commercial scale, cGMP manufacturing, QA/QC, and controlled substance handling with DEA registration. Two Indiana facilities totaling 34,400+ ft² of GMP space serving pharmaceutical, OTC, and wellness brand clients.
  • Packaging Services High-throughput US-based packaging and serialization services for liquid, creams, topicals, gels, semi-solids, and oral film products. Fully DSCSA-compliant serialized packaging with artwork, labeling, and final assembly support.

Quantifiable outcome

  • Over 2.5 billion PharmFilm doses shipped worldwide
  • +3 more outcomes

Companies that use Aquestive Therapeutics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Aquestive Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aquestive Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Assertio Holdings, Inc.coreOEM/ Whitelabel/ Licensing PartnerAssertio Holdings commercializes Sympazan (clobazam) oral film, an FDA-approved product utilizing Aquestive's PharmFilm technology. This is a licensing arrangement where Aquestive's technology is embedded in a commercialized pharmaceutical product.
  • Indivior, Inc.coreOEM/ Whitelabel/ Licensing PartnerIndivior commercializes Suboxone (buprenorphine and naloxone) sublingual film, an FDA-approved product utilizing Aquestive's PharmFilm technology. Suboxone was one of Aquestive's first two FDA-approved products in 2010.
  • Zambon UK LimitedminorOEM/ Whitelabel/ Licensing PartnerZambon UK Limited commercializes Emylif (riluzole) film orodispersible, an FDA-approved product utilizing Aquestive's PharmFilm technology for ALS treatment.
  • Hypera Pharma SAminorOEM/ Whitelabel/ Licensing PartnerHypera Pharma SA commercializes Ondif (ondansetron) orodisposable film utilizing Aquestive's PharmFilm technology for nausea and vomiting treatment.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Aquestive Therapeutics competitors and assessment

Company assessment

Direct peers

  • IntelGenx Technologies: IntelGenx is a specialty drug delivery company built around proprietary oral thin film technology, with a business model combining proprietary product development (similar to Aquestive's Anaphylm/Libervant pipeline) and CDMO/licensing partnerships (similar to Aquestive's Sympazan/Suboxone licensees). Both companies focus on transforming approved APIs into differentiated film-based dosage forms for partners.
  • LTS Lohmann Therapie-Systeme: LTS is a global leader in transdermal and oral thin film drug delivery systems, operating both proprietary development and contract development/manufacturing (CDMO) businesses. It is one of the most direct comparables to Aquestive's combined platform-plus-CDMO model and competes for similar pharmaceutical licensing partnerships.

Broad incumbents

  • Catalent: Catalent is a large, publicly traded global CDMO offering oral, injectable, and other drug delivery capabilities across a broad portfolio. While not specialized in oral thin films like Aquestive, Catalent competes for the same pharmaceutical CDMO customers and licensing partnerships and represents the scaled incumbent benchmark for the CDMO segment of Aquestive's business.
  • Viatris: Viatris owns the EpiPen franchise, the dominant injectable epinephrine rescue therapy and the direct competitive incumbent for Aquestive's Anaphylm. Viatris also licenses Suboxone sublingual film from Aquestive via its Indivior relationship history and is a critical reference point for assessing Anaphylm's addressable market and switching dynamics.
  • Collegium Pharmaceutical: Collegium is a specialty pharma focused on pain and CNS indications with a portfolio that includes film-based and abuse-deterrent products. Its specialty commercial model and CNS/pain therapeutic focus overlap meaningfully with Aquestive's planned direct commercialization of Libervant and CNS pipeline ambitions.

Emerging players

  • Neurelis: Neurelis developed Valtoco, a diazepam nasal spray approved for seizure clusters, positioning it as a direct therapeutic-area competitor to Aquestive's Libervant (diazepam buccal film). Both target the same patient population (seizure clusters in epilepsy) with non-injectable, non-rectal delivery alternatives and compete for similar neurology specialist and pediatric prescribing relationships.
  • BioDelivery Sciences International: BioDelivery Sciences (now part of Collegium Pharmaceutical) was a specialty pharma that commercialized film-based and buccal opioid products using its proprietary drug delivery platform. Its model of licensing and direct commercialization of differentiated formulations in CNS/pain indications is highly comparable to Aquestive's license-and-pipeline strategy.
  • Eagle Pharmaceuticals: Eagle Pharmaceuticals is a small-cap specialty pharma that develops and commercializes differentiated formulations of existing molecules, often through partnerships. Its specialty commercial infrastructure, small molecule reformulation focus, and reliance on licensing partners place it in a similar size and business model tier to Aquestive.
  • Tapemark: Tapemark is a private contract manufacturer specializing in transdermal patches and oral thin film drug delivery. It competes directly with Aquestive's CDMO segment for pharmaceutical and OTC brand customers seeking US-based film manufacturing capabilities, and its scale and capabilities are a useful comparator for that segment of Aquestive's business.

Others

  • Assertio Holdings: Assertio is the licensee that commercializes Aquestive's Sympazan (clobazam oral film) and also markets other specialty neurology products. As a direct commercial partner and adjacent specialty pharma operator, Assertio provides useful comparability for the economics and execution requirements of Aquestive's licensee model.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Aquestive Therapeutics social profiles

Digital presence

Aquestive Therapeutics compliance and trust

Trust signal

Compliance4 records

Aquestive Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aquestive Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Aquestive Therapeutics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aquestive Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aquestive Therapeutics

What does Aquestive Therapeutics do?

Aquestive Therapeutics is a specialty pharmaceutical company that develops, licenses, and manufactures pharmaceutical products using its proprietary PharmFilm oral film drug delivery technology and AdrenaVerse epinephrine prodrug platform. The company generates revenue through licensing its technology and FDA-approved products to pharmaceutical partners (Sympazan, Suboxone, Emylif, Ondif), providing CDMO manufacturing and packaging services to third-party brands, and advancing a proprietary pipeline (Anaphylm, Libervant, AQST-108) toward direct commercialization.

Is Aquestive Therapeutics a public or private company?

Aquestive Therapeutics is a public company. It is classified as public and is currently operating.

When was Aquestive Therapeutics founded?

Aquestive Therapeutics was founded in 2005. It employs 101 to 250 people.

Where is Aquestive Therapeutics based?

Aquestive Therapeutics is headquartered in Warren, United States, in the North America region.

How does Aquestive Therapeutics make money?

Three revenue lines are on record. Product Licensing & Royalty Revenue is the primary driver. The others are CDMO Manufacturing & Packaging Services and proprietary Product Commercialization.

Who are Aquestive Therapeutics's main competitors?

Direct peers on record are IntelGenx Technologies and LTS Lohmann Therapie-Systeme. Broad incumbents are Catalent, Viatris and Collegium Pharmaceutical. Emerging players are Neurelis, BioDelivery Sciences International, Eagle Pharmaceuticals and Tapemark. Assertio Holdings is listed as an others.

Does Aquestive Therapeutics have an API?

No public API is recorded for Aquestive Therapeutics.

What industry is Aquestive Therapeutics in?

Aquestive Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeAquestive Therapeutics to Present at Piper Sandler 38th Annual Healthcare Conference | AQST Stock NewsAquestive Therapeutics will present at the Piper Sandler Healthcare Conference on December 2, 2026, in New York City, with CEO Daniel Barber speaking. The company also plans one-on-one investor meetings and a webcast replay. The press release includes forward-looking statements about product development risks.Seeking AlphaAquestive Therapeutics: My Biotech Investment Framework Now Requires Me To DowngradeAquestive Therapeutics is downgraded from Buy to Sell due to commercial uncertainty around Anaphylm adoption. The analyst remains confident in FDA approval but lacks visibility on patient and physician adoption versus established Epi-pen habits. Neffy's commercial struggles post-approval highlight the difficulty of changing entrenched behaviors.Business & FinancialAquestive Therapeutics To Present At The Jefferies Global Healthcare ConferenceAquestive Therapeutics will present at the Jefferies Global Healthcare Conference on November 16 at 10:00 am GMT, with management hosting investor one-on-ones on November 16-18. The company, a leader in oral film delivery, is advancing Anaphylm and AQST-108 for allergic and dermatological indications. A webcast replay will be available for 30 days.American Banking and Market NewsAquestive Therapeutics (NASDAQ:AQST) Downgraded by Wall Street Zen to “Sell”Wall Street Zen downgraded Aquestive Therapeutics to a Sell rating, while other analysts hold Buy or Overweight ratings. The company missed Q3 EPS estimates at -$0.13 versus -$0.12, and revenue of $7.56 million fell short of the $11.02 million consensus. Insiders sold 58,750 shares over the past 90 days.YahooAquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...Aquestive Therapeutics reported Q3 2026 revenue of $7.6 million, down from $12.8 million, and a net loss of $16.5 million. The company guided full-year 2026 revenue to $46–50 million and expects to end the year with over $70 million in cash. It also out-licensed Libravant to Eton for $10 million upfront.Business & FinancialAquestive Therapeutics To Present Data At The 2026 ACAAI Annual MeetingAquestive Therapeutics will present data on its dibutepinephrine sublingual film at the 2026 ACAAI Annual Meeting, including oral and poster presentations. The product, Anaphylm, is conditionally approved by the FDA and would be the first oral rescue medication for anaphylaxis if fully approved.Seeking AlphaAquestive Therapeutics, Inc. (AQST) Q3 2026 Earnings Call TranscriptAquestive Therapeutics reported its Q3 2026 financial results and provided a business update on November 4, 2026. The call included remarks from CEO Dan Barber and CFO Ernie Toth, followed by a Q&A with other executives. The company's remarks correspond with the earnings release issued after market closed.Investing.comEarnings call transcript: Aquestive Therapeutics misses Q3 2026 estimatesAquestive Therapeutics reported Q3 2026 revenue of $7.6 million, down 40.6% year over year, and an adjusted loss of $0.13 per share, missing estimates. The company said the FDA accepted its Anaphylm resubmission with a PDUFA date of March 16, 2027, and expects year-end cash above $70 million.TradingViewAquestive Therapeutics Q3 2026 Earnings Call Is LiveAquestive Therapeutics' Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary can move markets as much as the earnings release itself.YahooAquestive Therapeutics: Q3 Earnings SnapshotAquestive Therapeutics reported a Q3 loss of $16.5 million, or 13 cents per share, with revenue of $7.6 million, missing the $11 million forecast. Shares fell to $3.89, down from $6.49 a year earlier.